Abstract

BackgroundFacial volume loss contributes significantly to facial aging. The 20-mg/mL hyaluronic acid (HA) formulation used in this study is a smooth, highly cohesive, viscous, fully reversible, volumizing filler indicated to restore facial volume. This first prospective study evaluated use in current aesthetic clinical practice.MethodsA pan-European evaluation conducted under guidelines of the World Association of Opinion and Marketing Research, the trial comprised a baseline visit (visit 1) and a follow-up (visit 2) at 14 ± 7 days posttreatment. Physicians photographed patients at each visit. Each patient was treated with the 20-mg/mL HA volumizing filler as supplied in standard packaging. Procedural details, aesthetic outcomes, safety, and physician and patient ratings of their experience were recorded.ResultsFifteen physicians and 70 patients (91% female; mean age: 50 years) participated. Mean volume loss at baseline was 3.7 (moderate) on the Facial Volume Loss Scale. Local anesthesia was used in 64.3% of cases. Most injections (85%) were administered with needles rather than cannulas. Of the 208 injections, 59% were in the malar region, primarily above the periosteum. Subcutaneous injections were most common for other sites. The mean total injection volume per patient was 4.6 mL. The mean volume loss score declined significantly (P < .001) to 2.1 at visit 2. On the Global Aesthetic Improvement Scale, 88% and 76% of the treatments were rated very much improved or much improved by physicians and patients, respectively. Of the physicians, 95.6% rated this HA filler as very or fairly easy to use. Similarly, 92% of patients were very likely or quite likely to return for treatment; nearly all (98%) would recommend this treatment to friends. Transient (mean duration: 5.5 days) injection-site adverse events (AEs) occurred in 24 patients. Bruising was the most common AE.ConclusionThe 20-mg/mL smooth, highly cohesive, viscous, volumizing HA filler was effective, well tolerated, and easy to use in current clinical practice. Participants were very likely to recommend this product to colleagues and friends, and patients would be very or quite likely to request this product for future treatments.

Highlights

  • Facial volume loss contributes significantly to facial aging

  • We report on the first prospective trial designed to assess how the 20-mg/mL smooth, cohesive hyaluronic acid (HA) volumizing filler is used in current clinical practice

  • We recommend evaluating for touch-ups at 1 month posttreatment to be sure that all edema, minimal, have completely resolved and HA water absorption is complete. This 20-mg/mL smooth, highly cohesive, viscous, fully reversible, resorbable, HA volumizing filler is indicated for restoring facial volume loss.[13]

Read more

Summary

Introduction

Facial volume loss contributes significantly to facial aging. The 20-mg/mL hyaluronic acid (HA) formulation used in this study is a smooth, highly cohesive, viscous, fully reversible, volumizing filler indicated to restore facial volume. Volume deficits resulting from the loss and repositioning of facial fat, as well as from skeletal remodeling, are increasingly appreciated as a fundamental component of facial aging.[1,4,5] The younger face is characterized by the harmony and balance captured in the classic heart shape or inverted triangle.[1,6] The reversal of this "triangle of beauty" as aging proceeds and as proportions rearrange is considered generally less aesthetically appealing With these changes, the convexities typical of a youthful appearance tend to flatten and droop

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call